A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer

Trial Profile

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs SGN LIV1A (Primary) ; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 26 Oct 2017 According to a Seattle Genetics media release, data from the study from SGN-LIV1A monotherapy were accepted for presentation at the San Antonio Breast Cancer Symposium.
    • 26 Jul 2017 Planned End Date changed from 1 May 2018 to 1 Dec 2019.
    • 26 Jul 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top